French pharma giant Sanofi kicked off 2021 with a $1.4 billion cash acquisition of U.K.-based Kymab to bolster the company’s presence in immunology.

BioSpace presented the NextGen Bio “Class of 2021,” a list of up-and-coming life sciences companies in North America that recently launched.

A panel of outside advisers to the U.S. Food and Drug Administration is expected to endorse emergency use of Moderna Inc.’s coronavirus vaccine during a meeting on Dec. 17, as the nation prepares to roll out a second vaccine.

AstraZeneca is acquiring Alexion Pharmaceuticals for $39 billion, with the deal expected to close in the third quarter of 2021.

AstraZeneca entered into a definitive agreement to acquire Alexion Pharmaceuticals for a total consideration to Alexion shareholders of $39 billion or $175 per share.

Kymera Therapeutics entered a strategic collaboration deal with Sanofi focused on developing and commercializing protein degrader therapies that target IRAK4 in immune-inflammatory diseases, such as rheumatoid arthritis.

Harbour BioMed closed a $102 million Series C funding round that will be used to advance the company’s oncology and immunology portfolio.

The U.S. Food and Drug Administration issued guidelines for where the regulatory agency will set the bar for approval of a vaccine for COVID-19.

Sana Biotechnology, which launched during 2019, raised $700 million in initial financing that will be used to advance the company’s discovery and development programs that create and deliver engineered cells as a treatment for different disease types.

Vividion Therapeutics’ proteomics screening platform and small molecule library will be leveraged by the San Diego-based company and Roche to target novel E3 ligases in addition to a variety of oncology and immunology therapy targets.